EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

This study is testing a combination of an EGFR-targeting antibody (a drug that blocks cancer cell growth signals), a PD-1 inhibitor (immunotherapy), and chemotherapy in patients with nasopharyngeal carcinoma (a cancer of the back of the nose and throat) that has come back or spread. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed nasopharyngeal carcinoma that has recurred or spread - You have not yet received any treatment for the recurrence or metastasis - Your general health is good (ECOG 0–1) - You have adequate blood, liver, and kidney function **You may NOT be eligible if...** - You have previously received chemotherapy, immunotherapy, or radiation for the recurrent/metastatic disease - You have active autoimmune disease - You have uncontrolled heart disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.